Understanding the Role of RNA-U4 in Cellular and Disease Processes

Target Name: RNU4-82P

NCBI ID: G106481198

RNU4-82P

Other Name(s): RNA, U4 small nuclear 82, pseudogene

Understanding the Role of RNA-U4 in Cellular and Disease Processes

RNA-U4 small nuclear RNA (snRNA), also known as U4 RNA, is a non-coding RNA molecule that plays a crucial role in various cellular processes. One of its functions is to act as a scaffold to recruit other RNA molecules to specific gene loci for protein synthesis. U4 RNA has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and respiratory infections.

The U4 RNA gene is located on chromosome 82 and has 19 open reading frames (ORFs) including a potential start codon. The ORFs include a highly conserved RNA-binding protein (RBP) domain, a unique feature that is specific to U4 snRNA, and a variable region that contains various non-coding elements. The U4 RNA gene has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

One of the unique features of U4 RNA is its ability to interact with other snRNAs. U4 RNA has been shown to form a complex with several other snRNAs, including U1 snRNA, U2 snRNA, U5 snRNA, and U6 snRNA. These interactions can alter the structure and function of the U4 RNA molecule and may have implications for its role in various cellular processes.

In addition to its role in cellular processes, U4 RNA has also been shown to play a role in disease. Several studies have identified U4 RNA as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and respiratory infections. For example, U4 RNA has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. This suggests that U4 RNA may be a useful target for cancer therapies that target RNA-based processes.

U4 RNA has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that U4 RNA is overexpressed in the brains of individuals with these conditions, and that these expressions are associated with the development of neurodegeneration. This suggests that U4 RNA may be a potential target for therapies aimed at reducing neurodegeneration.

In addition to its potential role in disease, U4 RNA has also been identified as a potential drug target. Studies have shown that U4 RNA can interact with various small molecules, including drugs that are currently being used to treat various diseases. For example, U4 RNA has been shown to interact with rapamycin, a drug that is used to treat cancer and other diseases. This interaction suggests that U4 RNA may be a potential target for rapamycin-based therapies.

Overall, RNA-U4 small nuclear RNA is a non-coding RNA molecule that plays a crucial role in various cellular processes. Its unique ability to interact with other snRNAs and its potential involvement in disease make it an attractive target for research and development of new therapies. Further studies are needed to fully understand the role of U4 RNA in cellular and disease processes, and to determine its potential as a drug target.

Protein Name: RNA, U4 Small Nuclear 82, Pseudogene

The "RNU4-82P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU4-82P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets